Pronounced therapeutic effect of samarium 153-ethylenediaminetetramethylene phosphonate in an orthotopic human osteosarcoma tibial tumor model.
Winderen
M
M
Department of Nuclear Medicine, Norwegian Radium Hospital, Oslo.
Kjønniksen
I
I
Fodstad
O
O
D000818:Animals; D001859:Bone Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D004195:Disease Models, Animal; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D009368:Neoplasm Transplantation; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D012516:Osteosarcoma / Q000473:pathology / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D051381:Rats; D011923:Rats, Nude; D012493:Samarium / Q000627:therapeutic use*; D013977:Tibia / Q000528:radiation effects
D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D012493:Samarium; C061972:samarium Sm-153 lexidronam